Integrated Strategy for Hit-to-Lead Optimization: The ‘DOTS’ approach

webinar

Thu, 27 Oct 2022, 16:00 CEST (Berlin)

Dr. Xavier Morelli, Centre de Recherche en Cancérologie de Marseille (CRCM), France

Integrated Strategy for Hit-to-Lead Optimization: The ‘DOTS’ approach

In recent decades, the identification of hits has been greatly facilitated by advances in high throughput screening (HTS) and the design of chemical libraries. It would be wishful to optimize the automation of the ‘hit-to-lead’ (H2L) process. Xavier will present an integrated strategy for the H2L optimization phase and the automated design of chemical probes called Diversity Oriented Target-Focused Synthesis (DOTS and CovaDOTS) approach.
In the ‘DOTS’ approach, a focused virtual library is generated by combining an activated fragment — corresponding to a substructure that binds to a target — with a collection of functionalized chemical blocks, using in silico encoded relevant chemical reactions. Target-specific compounds are selected by virtual screening, followed by in vitro synthesis and evaluation using a robotic platform. The proof of concept was successfully completed by the optimization of bromodomain inhibitors that lead to the validation of several compounds with an affinity that had improved by several orders of magnitude. The proposed process can be implemented in academic environments or biotechnology companies that desire an automation of these processes.

 

Register and tune in for a very exciting webinar.

1 Hoffer L. et al. J. Med. Chem. 2018 Jul 12;61(13):5719-5732; Carrasco K. et al., J. Med. Chem. 2022 Apr 14;65(7):5660-5674 

2 Hoffer L., et al. J. Chem. Inf. Model. 2019 2019 Apr 22;59(4):1472-1485

Current news

category
Events
UK-QSAR 2026: Registrations Are Open
January 21, 2026 16:45 CET
We’re excited to announce that registrations are now open for the UK-QSAR & Cheminformatics Society Meeting Spring 2026, taking place 21 April 2026 in Edinburgh (UK). This year’s meeting is co-hosted by BioSolveIT and Enamine and brings together cheminformatics and QSAR enthusiasts from academia and industry for a day of...
Read on
category
Events
AI/ML in Early Drug Discovery: From Data to Decisions (Hybrid Colloquium)
January 21, 2026 11:40 CET
We invite biotech/pharma investors, VCs, computational chemists, and medicinal chemists. Join Congruence Therapeutics for a focused industry colloquium exploring practical AI/ML workflows in early small molecule drug discovery. This event brings together experts to discuss how AI/ML is being applied in real discovery programs today, separating real impact from platform...
Read on
Tool of the Month - SpaceLight
January 19, 2026 13:46 CET
Spotlight on SpaceLight: Navigating Billions Efficiently In the search for the next lead candidate, medicinal chemists must balance structural similarity with the requirement for synthetic accessibility. This month, we spotlight SpaceLight, our algorithm designed to navigate the “beyond-billion” scale of Chemical Spaces with high accuracy.   What Does SpaceLight Do?...
Read on